Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367898 · ClinicalTrials.gov registry record · NA
Enhancing Cognitive Abilities With Comprehensive Training
A NA study, sponsored by Lumos Labs.
- Completed
- Registry status
- NA
- Development phase
- 11,470
- Enrollment target
NCT02367898: Completed NA study, sponsored by Lumos Labs.
NCT02367898 is a NA study that has completed, run by Lumos Labs. The registered enrollment target is 11,470 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (718% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02367898, a NA study, has completed, sponsored by Lumos Labs.
- COMPLETED
- Registry status
- NA
- Development phase
- 11,470 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the efficacy of an online cognitive training program against an active control condition in a large, randomized trial.
Primary Outcome
Aggregate cognitive performance, as measured by Grand Index, on seven neuropsychological assessments (Forward Memory Span, Reverse Memory Span, Grammatical Reasoning, Progressive Matrices, Go/No-Go, Arithmetic Reasoning, Two-Target Search)
Interventions
- OTHER Crossword Puzzles
- OTHER Lumosity Cognitive Training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,470 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-04 |
| Phase | NA |
What the finished NCT02367898 record still lists
NCT02367898 is an interventional study that assigns participants to a tested intervention. Its 11,470 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (718% higher).
The record links to 0 conditions, and to 2 interventions - of which Crossword Puzzles is the first listed.
NCT02367898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02367898 about?
NCT02367898 is a clinical study titled "Enhancing Cognitive Abilities With Comprehensive Training". The purpose of this study is to measure the efficacy of an online cognitive training program against an active control condition in a large, randomized trial.
What is the current status of trial NCT02367898?
This trial is currently completed. It is a NA study. The enrollment target is 11,470 participants. The study started on 2013-04. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02367898?
The interventions under investigation include: Crossword Puzzles (OTHER), Lumosity Cognitive Training (OTHER).
Who is sponsoring clinical trial NCT02367898?
This trial is sponsored by Lumos Labs, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02367898's enrollment target sits among peer trials
11,470 14th of 2000 higher than 1,987 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
- NCT07064473 · 11,800 participants · Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia